Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional...
SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage...
SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical...
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies...
Generated record revenue of $23.3 million for the first quarter of 2022 First patient dosed in Phase 3 clinical program evaluating DFD-29 for the...
Company to host conference call to discuss financial results and provide a corporate update on May 10, 2022 at 4:30 p.m. ET...
SCOTTSDALE, Ariz., April 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical...
Generated record net product revenues of $63.1 million for the full year 2021 Completed initial public offering of common stock and raised $30.6 million...
Company to hold conference call on March 23, 2022 at 4:30 p.m. ET...
Published Phase 2 clinical data show DFD-29 had approximately double the efficacy compared to Doxycycline capsules 40 mg on reducing total inflammatory...